J&J Tops Q4 Adjusted Earnings Estimates, But 2025 Sales Outlook Falls Short | Global News Avenue

Johnson & Johnson (Johnson & Johnson) released its fourth-quarter earnings report Wednesday morning, with adjusted profit beating expectations while the company’s sales forecast for the next fiscal year came in below expectations.

The drug and medical device maker reported sales of $22.52 billion in 2017. incomequeue vs. analyst estimates Compiled by Visible Alpha. corporate profit However, the company’s results fell short of $3.43 billion, or $1.41 per share, compared with analysts’ expectations of $4.41 billion, or $1.79 per share.

After taking into account one-time costs Amortization of assets and acquisition related costsJohnson & Johnson Adjusted net profit Its revenue was $4.94 billion, slightly above analysts’ expectations of $4.88 billion.

The company also outlined its FY2025 Forecastas it expects revenue between $89.2 billion and $90 billion, as well as adjusted earnings per share The range is $10.50 to $10.70. Analysts are currently expecting revenue figures of $91.18 billion and adjusted earnings per share of $10.54, according to estimates from Visible Alpha.

Sales of the company’s pharmaceuticals and medical technology divisions increased 4.4% and 6.7% respectively from the same period last year.

Shares of Johnson & Johnson were down more than 1% on Wednesday morning.